O	0	10	Comparison
O	11	13	of
B-intervention	14	27	pegfilgrastim
I-intervention	28	30	on
I-intervention	31	34	day
I-intervention	35	36	2
O	37	39	vs
O	39	40	.
B-control	41	44	day
I-control	45	46	4
O	47	49	as
O	50	57	primary
O	58	69	prophylaxis
O	70	72	of
O	73	80	intense
O	81	85	dose
O	85	86	-
O	86	91	dense
O	92	104	chemotherapy
O	105	107	in
O	108	116	patients
O	117	121	with
O	122	126	node
O	126	127	-
O	127	135	positive
O	136	143	primary
O	144	150	breast
O	151	157	cancer
O	158	164	within
O	165	168	the
O	169	180	prospective
O	180	181	,
O	182	187	multi
O	187	188	-
O	188	194	center
O	195	199	GAIN
O	200	205	study
O	205	206	:
O	207	208	(
O	208	211	GBG
O	212	214	33
O	214	215	)
O	215	216	.

O	217	228	Preliminary
O	229	233	data
O	234	241	suggest
O	242	246	that
O	247	260	pegfilgrastim
O	261	266	given
O	267	269	on
O	270	273	day
O	274	275	4
O	276	277	(
O	277	279	P4
O	279	280	)
O	281	286	might
O	287	289	be
O	290	298	superior
O	299	301	to
O	302	315	pegfilgrastim
O	316	318	on
O	319	322	day
O	323	324	2
O	325	326	(
O	326	328	P2
O	328	329	)
O	330	332	in
O	333	341	reducing
O	342	347	grade
O	348	349	4
O	350	360	leucopenia
O	360	361	.

B-eligibility	362	370	Patients
I-eligibility	371	375	with
I-eligibility	376	380	node
I-eligibility	380	381	-
I-eligibility	381	389	positive
I-eligibility	390	397	primary
I-eligibility	398	404	breast
I-eligibility	405	411	cancer
I-eligibility	412	421	receiving
I-eligibility	422	432	epirubicin
I-eligibility	432	433	-
I-eligibility	433	443	paclitaxel
I-eligibility	443	444	-
I-eligibility	444	460	cyclophosphamide
I-eligibility	461	473	chemotherapy
O	474	478	were
O	479	489	randomized
O	490	492	to
O	493	500	receive
O	501	503	P2
O	504	510	versus
O	511	513	P4
O	513	514	.

O	515	522	Primary
O	523	531	endpoint
O	532	535	was
B-outcome-Measure	536	546	leucopenia
I-outcome-Measure	547	552	grade
I-outcome-Measure	553	554	4
O	554	555	,
O	556	564	assuming
O	565	566	a
O	567	571	risk
O	572	581	reduction
O	582	584	of
O	585	587	50
O	587	588	%
O	589	593	with
O	594	596	P4
O	597	601	from
O	602	604	50
O	604	605	%
O	606	608	in
O	609	611	P2
O	612	614	to
O	615	617	25
O	617	618	%
O	619	623	with
O	624	626	P4
O	626	627	.

B-total-participants	628	633	Three
I-total-participants	633	634	-
I-total-participants	634	641	hundred
I-total-participants	642	647	fifty
I-total-participants	647	648	-
I-total-participants	648	651	one
O	652	660	patients
O	661	665	were
O	666	676	randomized
O	677	679	to
O	680	682	P2
O	683	684	(
O	684	685	n
O	686	687	=
B-intervention-participants	688	691	174
O	691	692	)
O	693	699	versus
O	700	702	P4
O	703	704	(
O	704	705	n
O	706	707	=
B-control-participants	708	711	177
O	711	712	)
O	712	713	.

O	714	717	The
B-outcome	718	722	rate
I-outcome	723	725	of
I-outcome	726	736	leucopenia
I-outcome	737	738	(
I-outcome	738	743	grade
I-outcome	744	745	4
I-outcome	745	746	)
O	747	750	was
B-iv-bin-percent	751	753	47
I-iv-bin-percent	753	754	.
I-iv-bin-percent	754	755	1
I-iv-bin-percent	755	756	%
O	757	761	with
O	762	764	P2
O	765	768	and
B-cv-bin-percent	769	771	42
I-cv-bin-percent	771	772	.
I-cv-bin-percent	772	773	0
I-cv-bin-percent	773	774	%
O	775	779	with
O	780	782	P4
O	783	784	(
O	784	785	p
O	786	787	=
O	788	789	0
O	789	790	.
O	790	793	387
O	793	794	)
O	794	795	,
B-outcome	796	807	neutropenia
I-outcome	808	809	(
I-outcome	809	814	grade
I-outcome	815	816	3
I-outcome	817	818	+
I-outcome	819	820	4
I-outcome	820	821	)
O	822	825	was
B-iv-bin-percent	826	828	47
I-iv-bin-percent	828	829	.
I-iv-bin-percent	829	830	9
I-iv-bin-percent	830	831	%
O	832	838	versus
B-cv-bin-percent	839	841	40
I-cv-bin-percent	841	842	.
I-cv-bin-percent	842	843	8
I-cv-bin-percent	843	844	%
O	845	846	(
O	846	847	p
O	848	849	=
O	850	851	0
O	851	852	.
O	852	855	337
O	855	856	)
O	856	857	,
B-outcome	858	860	FN
O	861	864	was
B-iv-bin-percent	865	866	4
I-iv-bin-percent	866	867	.
I-iv-bin-percent	867	868	7
I-iv-bin-percent	868	869	%
O	870	876	versus
B-cv-bin-percent	877	878	8
I-cv-bin-percent	878	879	.
I-cv-bin-percent	879	880	0
I-cv-bin-percent	880	881	%
O	882	883	(
O	883	884	p
O	885	886	=
O	887	888	0
O	888	889	.
O	889	892	271
O	892	893	)
O	893	894	,
O	895	898	and
B-outcome	899	909	infections
O	910	913	was
B-iv-bin-percent	914	916	29
I-iv-bin-percent	916	917	.
I-iv-bin-percent	917	918	9
I-iv-bin-percent	918	919	%
O	920	926	versus
B-cv-bin-percent	927	929	25
I-cv-bin-percent	929	930	.
I-cv-bin-percent	930	931	4
I-cv-bin-percent	931	932	%
O	933	934	(
O	934	935	p
O	936	937	=
O	938	939	0
O	939	940	.
O	940	943	404
O	943	944	)
O	944	945	,
O	946	958	respectively
O	958	959	.

O	960	964	This
O	965	970	study
O	971	977	failed
O	978	980	to
O	981	992	demonstrate
O	993	997	that
O	998	1011	pegfilgrastim
O	1012	1014	on
O	1015	1018	day
O	1019	1020	4
O	1021	1024	was
O	1025	1029	more
O	1030	1041	efficacious
O	1042	1046	than
O	1047	1049	on
O	1050	1053	day
O	1054	1055	2
O	1056	1060	with
O	1061	1068	respect
O	1069	1071	to
O	1072	1077	grade
O	1078	1079	4
O	1080	1090	leucopenia
O	1091	1092	(
O	1092	1095	the
O	1096	1103	primary
O	1104	1112	endpoint
O	1112	1113	)
O	1113	1114	,
O	1115	1122	febrile
O	1123	1134	neutropenia
O	1134	1135	,
O	1136	1138	or
O	1139	1149	infections
O	1149	1150	.
